Post Marketing Surveillance of JARDIANCE in Chronic Kidney Disease

Sponsor
Boehringer Ingelheim
Study ID
NCT06527846
Status
Active Not Recruiting

Conditions

  • Kidney Disease, Chronic

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • JARDIANCE® — DRUG
    JARDIANCE®

Study Details

Study objective is to investigate the safety and effectiveness of long-term daily use of JARDIANCE® Tablets in patients with chronic kidney disease under real-world use.

Key Dates

First listed
Jul 30, 2024
Start date
Oct 22, 2024
Status verified
Mar 2026
Primary completion
Mar 31, 2027
Completion
Mar 31, 2027

Study Design

Enrollment
1,024 participants (actual)

Arms

  • Arm: Patients with chronic kidney disease (CKD)

Primary Outcome Measure

Incidence of Adverse Drug Reactions (ADRs) [ Time Frame: Up to 52 weeks ]

Related Studies